Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
Crossref DOI link: https://doi.org/10.1007/s13300-020-00804-2
Published Online: 2020-04-10
Published Print: 2020-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yu, Miao
Yuan, Guo Yue
Zhang, Bin
Wu, Hai Ya
Lv, Xiao Feng
Funding for this research was provided by:
Eli Lilly and Company
Text and Data Mining valid from 2020-04-10
Version of Record valid from 2020-04-10
Article History
Received: 19 September 2019
First Online: 10 April 2020